



Fine powders - Coatings additives

TYPICAL PROPERTIES OF ORGASOL[®] POWDERS

ORGASOL [®] BY ARKEMA	Polyamide	Average particle size μm	Specific surface area m^2/g	Melting point $^{\circ}\text{C}$	Comments
2001 UD NAT1	12	5	9	177	
2001 UD NAT2	12	5	9	177	Food contact approved
2001 EXD NAT1	12	10	4	177	
2002 EXD NAT1	12	10	1.5	177	Food contact approved
2002 D NAT1	12	20	1	177	
2002 ES3 NAT3	12	30	1	177	
2002 ES4 NAT3	12	40	1	177	
2002 ES5 NAT3	12	50	1	177	
2002 ES6 NAT3	12	60	1	177	
1002 D NAT1	6	20	2	217	
1002 ES5 NAT1	6	50	<1	217	
3501 EXD NAT 1	6/12	10	20	143	
3502 D NAT1	6/12	20	6	143	

Particle size is measured using a Coulter-Multisizer III granulometer

TYPICAL PROPERTIES OF RILSAN[®] POWDERS

RILSAN [®] BY ARKEMA	Polyamide	Average particle size μm	Specific surface area m^2/g	Melting point $^{\circ}\text{C}$	Comments
D30 NAT	11	21-27	< 1	186	
D40 NAT	11	27-31	< 1	186	
D50 NAT	11	40-46	<1	186	
D60 NAT	11	43-55	< 1	186	
D80 NAT	11	95-105	< 1	186	
ES MAC COLOR	11	28-36	< 1	186	several colors

Particle size is measured using a laser granulometer



Arkema France - A French « Société Anonyme » registered with the Commercial and Companies Register of Nanterre (France) - Stock number 319 632 790
MARCOCOM Europe / 02.2015 / TPA - photos: Getty image, iStock - Design: AS

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations. Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices. It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Orgasol® and Rilsan® are registered trademark of Arkema

extremematerials-arkema.com

ARKEMA
INNOVATIVE CHEMISTRY

Headquarters: Arkema France
420, rue d'Estienne d'Orves
92705 Colombes Cedex – France
Tél. : 33 (0)1 49 00 80 80
Fax : 33 (0)1 49 00 83 96
arkema.com